Shanghai Fosun Pharmaceutical (Group) (SFOSF) Stock Price, News & Analysis

Company Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China‐based healthcare company and a core subsidiary of Fosun International. The company operates across drug manufacturing, distribution and retail services, and health management. Its product portfolio includes generic and proprietary small‐molecule drugs, bio‐pharmaceuticals, vaccines and traditional Chinese patent medicines. Through integrated R&D capabilities and strategic partnerships, Fosun Pharmaceutical pursues innovation across therapeutic areas such as oncology, cardiovascular, metabolic and infectious diseases.

The pharmaceutical manufacturing segment encompasses chemical pharmaceuticals, Chinese patent medicines and biological products, while the distribution arm manages one of the largest drug distribution networks in China, supplying hospitals, clinics and retail pharmacies. In addition, the company operates a nationwide chain of retail pharmacies and health management service centers, offering diagnostics, health check‐ups and chronic disease management programs. This integrated approach enables Fosun Pharmaceutical to deliver end‐to‐end solutions from drug discovery to patient‐centric care.

Founded in 1994 and reorganized in 2003, Shanghai Fosun Pharmaceutical was listed on the Shanghai Stock Exchange in 1998 and on the Hong Kong Stock Exchange in 2004. As part of the Fosun group, it leverages global R&D collaborations and overseas acquisitions to enhance its technology platform and broaden its geographic reach. While its core markets remain Mainland China and Hong Kong, the company has expanded into Southeast Asia, Europe and North America through joint ventures, licensing agreements and targeted investments.

Governed by a board with representation from Fosun International and led by seasoned industry executives, Shanghai Fosun Pharmaceutical continues to invest in innovation platforms, advanced manufacturing facilities and digital health initiatives. The company’s strategic focus on research, quality production and comprehensive healthcare services underpins its goal of building a vertically integrated pharmaceutical ecosystem that addresses evolving patient needs worldwide.

Key Stats

• Today's Range: $1.93 to $1.93
• 50-Day Range: $1.93 to $2.20
• 52-Week Range: $1.93 to $3.50
• Volume: 2,958 shs
• Average Volume: 1,371 shs
• Market Capitalization: N/A
• P/E Ratio: 1.65
• Dividend Yield: 13.98%
• Price Target: N/A
• Consensus Rating: N/A

Shanghai Fosun Pharmaceutical (Group) Stock Analysis - MarketRank™

Shanghai Fosun Pharmaceutical (Group) scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shanghai Fosun Pharmaceutical (Group).

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shanghai Fosun Pharmaceutical (Group) is 1.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.19.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shanghai Fosun Pharmaceutical (Group) is 1.65, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.25.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shanghai Fosun Pharmaceutical (Group) has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Shanghai Fosun Pharmaceutical (Group) has recently increased by 96.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shanghai Fosun Pharmaceutical (Group) pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shanghai Fosun Pharmaceutical (Group) does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shanghai Fosun Pharmaceutical (Group) is 23.08%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Shanghai Fosun Pharmaceutical (Group) has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Shanghai Fosun Pharmaceutical (Group) this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shanghai Fosun Pharmaceutical (Group) insiders have not sold or bought any company stock.

Percentage Held by Institutions

4.64% of the stock of Shanghai Fosun Pharmaceutical (Group) is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SFOSF
• CIK: N/A
• Web: www.fosunpharma.com
• Phone: 86-21-3398-7000
• Fax: N/A
• Employees: 40,370
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 1.65
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A